Cingulate Q3 net loss widens 5% to $7.73 million
- Cingulate's third-quarter net loss widened 5% year over year to $7.73 million.
- Selling, general and administrative expenses rose 46% to $4.58 million, driven by expanded commercial readiness capabilities.
- Cash totaled $23.19 million at September 30, 2026, and was expected to fund operations into mid-2027.
- CTx-1301 manufacturing remediation was substantially complete, with NDA resubmission expected between December 2026 and January 2027.
- The FDA's Complete Response Letter requested additional manufacturing information but raised no clinical safety or efficacy concerns.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cingulate Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611131645PRIMZONEFULLFEED9877620) on November 13, 2026, and is solely responsible for the information contained therein.